FOXC1

protein-coding

forkhead box C1, the group of Forkhead boxes

Gene summary

This gene belongs to the forkhead family of transcription factors which is characterized by a distinct DNA-binding forkhead domain. The specific function of this gene has not yet been determined; however, it has been shown to play a role in the regulation of embryonic and ocular development. Mutations in this gene cause various glaucoma phenotypes including primary congenital glaucoma, autosomal dominant iridogoniodysgenesis anomaly, and Axenfeld-Rieger anomaly. [provided by RefSeq, Jul 2008]

Previous symbols:
  • FKHL7
  • IRID1

MANE transcript

NM_001453.3

Inheritance

AD

ClinVar variants

P:168U:400B:171

Top phenotype

Axenfeld-Rieger syndrome, type 3; Anterior segment dysgenesis 3

gnomAD constraint

pLI —, LoF o/e 0

Max pathogenic AF

—

Genomic locus

chr6:1,609,915-1,613,897

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~4.0 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

Axenfeld-Rieger syndromeSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0019187

Submitter: Orphanet

Peters anomalySUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0011414

Submitter: Orphanet

Axenfeld-Rieger syndrome type 3STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0011233

Submitter: PanelApp Australia

isolated aniridiaSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0007119

Submitter: Orphanet

FOXC1-related anterior segment dysgenesisDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0100235

Submitter: ClinGen

The *FOXC1* gene was first reported in relation to anterior segment dysgenesis in 1998 (PMID: 9620769). The specific disease entity, anterior segment dysgenesis 3, is one of eight such conditions distinguished by a single monogenic cause. Onset of symptoms is variable, and affected patients can be diagnosed in infancy or as late as in adulthood. Findings are primarily ocular and localized to the anterior segment, and frequently include prominent and anteriorly displaced Schwalbe’s line, iris hypoplasia, ectopia pupillae, abnormal pupil shape and iridocorneal adhesions. Glaucoma is a well-characterized phenotype that develops with approximately 50-75% penetrance, while corneal neovascularization and Peters anomaly have been observed in some affected individuals. Some affected patients exhibit additional extraocular symptoms, and are not typically diagnosed with anterior segment dysgenesis 3, but rather with Axenfeld-Rieger syndrome 3. Extraocular symptoms can include hypertelorism, midface retrusion, maxillary hypoplasia, microdontia, hearing loss, protuberant umbilical skin, heart anomalies, mild cerebellar vermis hypoplasia, and dilated perivascular spaces. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, the molecular mechanism (monoallelic loss of function) and mode of inheritance (autosomal dominant) were found to be consistent among patients with anterior segment dysgenesis 3 and Axenfeld-Rieger syndrome 3, while the phenotypic variability between them appeared to represent a spectrum of disease rather than separate disease entities. Therefore, cases caused by inherited FOXC1 variants have been lumped into a single disease entity, referred to as FOXC1-related anterior segment dysgenesis (MONDO:0100235). Ten suspected pathogenic variants were scored as part of this curation (one nonsense, three frameshift, and six missense affecting the Forkhead domain of the encoded protein), which have been collectively reported in ten probands in five publications (PMID: 9620769, PMID: 9792859, PMID: 10713890, PMID: 17210863, PMID: 11170889). More case-level evidence is available in the literature (PMID: 11170889, PMID: 16936096), but its inclusion in this curation was not necessary to reach the maximum score for genetic evidence (12 points). It is important to note that a subset of affected patients exhibit either loss or gain of *FOXC1* copy number, highlighting the importance of precise *FOXC1* gene dosage in anterior segment development (PMID: 11170889). Patients harboring duplications in *FOXC1* exhibit a particularly severe prognosis for the development of glaucoma relative to patients with other types of *FOXC1* variants (PMID: 17197537). However, these probands were not scored as part of this curation. While *FOXC1* variants and copy number alterations are estimated to be present in approximately 24% of patients with anterior segment dysgenesis (PMID: 20881294), the high GC content of the locus causes sequencing challenges that may lead to under-identification of *FOXC1* variants by next-generation sequencing-based panels. This gene-disease relationship has not been studied in case-control studies at the single variant level or aggregate variant level. The mechanism of pathogenicity appears to be monoallelic loss of function, characterized in some cases by truncation of the majority of the protein product and in other cases by missense variants affecting the Forkhead domain that trigger defects in DNA binding, transactivation, and/or nuclear localization (PMID: 11179011). All probands scored in this curation harbored one variant allele within the *FOXC1* locus. This gene-disease association is also supported by biochemical evidence that FOXC1 protein functions as a transcription factor to coordinate normal development of the ocular anterior segment (PMID: 11782474, PMID: 17993506) and to promote the survival of trabecular meshwork cells (PMID: 24556684), which are known to regulate intraocular pressure and exhibit reduced cellularity in glaucoma. FOXC1 physically interacts with and colocalizes with PITX2, another transcription factor associated with anterior segment dysgenesis through an autosomal dominant mode of inheritance (PMID: 16449236). This interaction may explain why *FOXC1* variants and *PITX2* variants appear to act as modifiers of Axenfeld-Rieger syndrome severity when present in the same family (PMID: 21837767). *FOXC1* missense variants exogenously expressed in non-patient cells exhibit disruption of nuclear localization or DNA binding in some cases, and reduced transactivation of a reporter gene in all cases (PMID: 14506133). Phenotypes of affected human patients are recapitulated by various model organisms with *FOXC1* loss-of-function, including abnormalities in ocular morphology and vascularization in both zebrafish (PMID: 19458328, PMID: 32720677) and mice (PMID: 22171010). A heterozygous knockout mouse model also exhibited ectopia pupillae, irido-corneal attachments, hypoplastic iris stroma, and trabecular meshwork abnormalities (PMID: 10767326). In summary, *FOXC1* is Definitively associated with FOXC1-related anterior segment dysgenesis. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a Definitive classification. This classification was approved by the ClinGen Glaucoma and Neuro-Ophthalmology Gene Curation Expert Panel on November 18th, 2021 (SOP Version 8).

Axenfeld anomalySUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0020368

Submitter: Orphanet

Rieger anomalySUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0019628

Submitter: Orphanet

aniridiaSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0019172

Submitter: Genomics England PanelApp

anterior segment dysgenesis 3STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0024456

Submitter: Labcorp Genetics (formerly Invitae)

Axenfeld-Rieger syndrome type 3DEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0011233

Submitter: G2P

Axenfeld-Rieger syndrome type 3STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0011233

Submitter: Labcorp Genetics (formerly Invitae)

Clinical Genomic Database (CGD)

Axenfeld-Rieger syndrome, type 3; Anterior segment dysgenesis 3AD

Manifestation: Audiologic/Otolaryngologic; Cardiovascular; Musculoskeletal; Ophthalmologic

Intervention: Cardiovascular; Ophthalmologic; Pharmacogenomic

Rationale: Individuals with Axenfeld-Rieger anomaly have a high risk of developing glaucoma, but treatment may not be effective in the majority of cases; Awareness of cardiac anomalies (eg, valvular anomalies leading to congestive heart failure have been described) may allow early detection and treatment; Agents that may contribute to glaucoma should be avoided

Refs: 9445211; 9792859; 9620769; 11004268; 11007653; 10713890; 12036988; 11170889; 12036988; 12614756; 12614756; 17197537; 18498376; 19668217; 19793056; 23239455Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to FOXC1 variants in ClinVar

16 Conditions Cataloged
Axenfeld-Rieger syndrome type 3Total: 603
not providedTotal: 155
Anterior segment dysgenesis 3Total: 137
Inborn genetic diseasesTotal: 124
FOXC1-related disorderTotal: 99
not specifiedTotal: 66
FOXC1-related disordersTotal: 22
Congenital anomaly of kidney and urinary tractTotal: 7

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_001453.3. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
37
clinvar
144
clinvar
4
clinvar
185
missense
16
clinvar
26
clinvar
361
clinvar
21
clinvar
2
clinvar
426
nonsense
23
clinvar
10
clinvar
33
start loss
2
clinvar
1
clinvar
3
frameshift
54
clinvar
36
clinvar
2
clinvar
92
splice donor/acceptor (+/-2bp)
0
Total95734001656739

Highest pathogenic variant AF is 0.000010951958

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 2 of 2 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_001453.3RefSeqNP_001444.21MANE Select
ENST00000645831.2EnsemblENSP00000493906.11MANE Select

Model Organisms & Knockout Phenotypes

Observed phenotypic effects in mouse and zebrafish models

Gene / ModelOrganismObserved Phenotype
foxc1bDanio rerio

Structure: blood vessel morphogenesis

Quality: disrupted

abnormal

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • HH-Core
  • Heart Development
  • Mesodermal Commitment Pathway
  • BMP Signaling Pathway in Eyelid Development

Biological Process

  • negative regulation of transcription by RNA polymerase II
  • angiogenesis
  • ovarian follicle development
  • eye development
  • ureteric bud development

Molecular Function

  • RNA polymerase II regulatory region sequence-specific DNA binding
  • DNA-binding transcription factor activity, RNA polymerase II-specific
  • transcription coactivator binding
  • DNA-binding transcription activator activity, RNA polymerase II-specific
  • DNA binding

Cellular Component

  • nucleus
  • nucleoplasm
  • nuclear heterochromatin
  • cytosol

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000380874
Coding exons
1
Length
3447
Individuals with no LoFs
0
Homozygous LoFs
0
Heterozygous LoFs
0
Defined
0
p
0.00
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense0.3422132280.9360.00001093504
Missense (PolyPhen)5892.5460.626721311
Synonymous-4.901671041.610.000005421162
Loss of Function2.8809.630.004.16e-7139

Population LoF Frequency

PopulationCAFp-valueStatus
African00.0absent
Latino/Admixed American00.0absent
Ashkenazi Jewish00.0absent
East Asian00.0absent
Finnish00.0absent
European (Non-Finnish)00.0absent
South Asian00.0absent
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: DNA-binding transcriptional factor that plays a role in a broad range of cellular and developmental processes such as eye, bones, cardiovascular, kidney and skin development (PubMed:11782474, PubMed:15299087, PubMed:15684392, PubMed:16492674, PubMed:27907090, PubMed:14506133, PubMed:14578375, PubMed:15277473, PubMed:16449236, PubMed:17210863, PubMed:19793056, PubMed:19279310, PubMed:25786029, PubMed:27804176). Acts either as a transcriptional activator or repressor (PubMed:11782474). Binds to the consensus binding site 5'-[G/C][A/T]AAA[T/C]AA[A/C]-3' in promoter of target genes (PubMed:7957066, PubMed:11782474, PubMed:12533514, PubMed:14506133, PubMed:19793056, PubMed:27804176). Upon DNA-binding, promotes DNA bending (PubMed:7957066, PubMed:14506133). Acts as a transcriptional coactivator (PubMed:26565916). Stimulates Indian hedgehog (Ihh)- induced target gene expression mediated by the transcription factor GLI2, and hence regulates endochondral ossification (By similarity). Acts also as a transcriptional coregulator by increasing DNA-binding capacity of GLI2 in breast cancer cells (PubMed:26565916). Regulates FOXO1 through binding to a conserved element, 5'-GTAAACAAA-3' in its promoter region, implicating FOXC1 as an important regulator of cell viability and resistance to oxidative stress in the eye (PubMed:17993506). Cooperates with transcription factor FOXC2 in regulating expression of genes that maintain podocyte integrity (By similarity). Promotes cell growth inhibition by stopping the cell cycle in the G1 phase through TGFB1-mediated signals (PubMed:12408963). Involved in epithelial- mesenchymal transition (EMT) induction by increasing cell proliferation, migration and invasion (PubMed:20406990, PubMed:22991501). Involved in chemokine CXCL12-induced endothelial cell migration through the control of CXCR4 expression (By similarity). Plays a role in the gene regulatory network essential for epidermal keratinocyte terminal differentiation (PubMed:27907090). Essential developmental transcriptional factor required for mesoderm-derived tissues, such as the somites, skin, bone and cartilage. Positively regulates CXCL12 and stem cell factor expression in bone marrow mesenchymal progenitor cells, and hence plays a role in the development and maintenance of mesenchymal niches for haematopoietic stem and progenitor cells (HSPC). Plays a role in corneal transparency by preventing both blood vessel and lymphatic vessel growth during embryonic development in a VEGF-dependent manner. Involved in chemokine CXCL12-induced endothelial cell migration through the control of CXCR4 expression (By similarity). May function as a tumor suppressor (PubMed:12408963). {ECO:0000250|UniProtKB:Q61572, ECO:0000269|PubMed:11782474, ECO:0000269|PubMed:12408963, ECO:0000269|PubMed:12533514, ECO:0000269|PubMed:14506133, ECO:0000269|PubMed:14578375, ECO:0000269|PubMed:15277473, ECO:0000269|PubMed:15299087, ECO:0000269|PubMed:15684392, ECO:0000269|PubMed:16449236, ECO:0000269|PubMed:16492674, ECO:0000269|PubMed:17210863, ECO:0000269|PubMed:17993506, ECO:0000269|PubMed:19279310, ECO:0000269|PubMed:19793056, ECO:0000269|PubMed:20406990, ECO:0000269|PubMed:22991501, ECO:0000269|PubMed:25786029, ECO:0000269|PubMed:26565916, ECO:0000269|PubMed:27804176, ECO:0000269|PubMed:27907090, ECO:0000269|PubMed:7957066}.;
Disease
DISEASE: Axenfeld-Rieger syndrome 3 (RIEG3) [MIM:602482]: An autosomal dominant disorder of morphogenesis that results in abnormal development of the anterior segment of the eye, and results in blindness from glaucoma in approximately 50% of affected individuals. Features include posterior corneal embryotoxon, prominent Schwalbe line and iris adhesion to the Schwalbe line, hypertelorism, hypodontia, sensorineural deafness, redundant periumbilical skin, and cardiovascular defects such as patent ductus arteriosus and atrial septal defect. When associated with tooth anomalies, the disorder is known as Rieger syndrome. {ECO:0000269|PubMed:11170889, ECO:0000269|PubMed:11179011, ECO:0000269|PubMed:11589884, ECO:0000269|PubMed:11740218, ECO:0000269|PubMed:12454026, ECO:0000269|PubMed:12592227, ECO:0000269|PubMed:14506133, ECO:0000269|PubMed:14578375, ECO:0000269|PubMed:15277473, ECO:0000269|PubMed:15477465, ECO:0000269|PubMed:16449236, ECO:0000269|PubMed:16936096, ECO:0000269|PubMed:17210863, ECO:0000269|PubMed:17653043, ECO:0000269|PubMed:19279310, ECO:0000269|PubMed:23239455, ECO:0000269|PubMed:24914578, ECO:0000269|PubMed:25786029, ECO:0000269|PubMed:27804176, ECO:0000269|PubMed:9792859}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Anterior segment dysgenesis 3 (ASGD3) [MIM:601631]: A form of anterior segment dysgenesis, a group of defects affecting anterior structures of the eye including cornea, iris, lens, trabecular meshwork, and Schlemm canal. Anterior segment dysgeneses result from abnormal migration or differentiation of the neural crest derived mesenchymal cells that give rise to components of the anterior chamber during eye development. Different anterior segment anomalies may exist alone or in combination, including iris hypoplasia, enlarged or reduced corneal diameter, corneal vascularization and opacity, posterior embryotoxon, corectopia, polycoria, abnormal iridocorneal angle, ectopia lentis, and anterior synechiae between the iris and posterior corneal surface. Clinical conditions falling within the phenotypic spectrum of anterior segment dysgeneses include aniridia, Axenfeld anomaly, Reiger anomaly/syndrome, Peters anomaly, and iridogoniodysgenesis. ASGD3 inheritance is autosomal dominant. {ECO:0000269|PubMed:12614756, ECO:0000269|PubMed:18484311, ECO:0000269|PubMed:19279310, ECO:0000269|PubMed:19793056, ECO:0000269|PubMed:20881294, ECO:0000269|PubMed:9620769}. Note=The disease is caused by mutations affecting the gene represented in this entry.;

Recessive Scores

pRec
0.299

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
N
Indispensability score
0.323

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.